Finding Potential Drug Targets for Pre-Eclampsia Using Mendelian Randomisation and Colocalisation Analysis

Area of Science:

• Genetics
• Proteomics
• Obstetrics

Background:

• Pre-eclampsia (PE) is a significant pregnancy complication requiring novel therapeutic targets.
• Whole proteome-wide Mendelian randomization (MR) and colocalization analyses were employed to discover potential drug targets for PE.

Purpose of the Study:

• To identify potential therapeutic targets for pre-eclampsia (PE) by investigating causal associations with plasma proteins.
• To utilize whole proteome-wide Mendelian randomization (MR) and colocalization analyses for target discovery.

Main Methods:

• A two-sample MR study utilized summary statistics from 734 plasma proteins and PE/eclampsia data from the FinnGen consortium.
• Causal associations were assessed using Wald ratio and Inverse Variance Weighted (IVW) methods.
• Colocalization analyses examined shared variants between identified proteins and PE.

Main Results:

• Genetically predicted levels of 42 plasma proteins were associated with PE risk (Benjamini-Hochberg correction).
• Nineteen proteins were linked to increased PE risk, while 23 proteins were associated with reduced PE risk.
• Six proteins (VWA2, ACHE, CXCL10, PZP, AHSG, UROS) demonstrated high evidence of colocalization with PE.

Conclusions:

• The study identified 42 proteins with a causal association with PE risk.
• These proteins represent promising candidates for novel therapeutic targets for pre-eclampsia.
• Further research into these proteins could lead to new treatments for PE.